Nurix Therapeutics (NASDAQ:NRIX – Get Rating) is scheduled to be posting its quarterly earnings results on Friday, January 27th.
Nurix Therapeutics Stock Down 2.9 %
NASDAQ NRIX traded down $0.36 during mid-day trading on Thursday, hitting $12.10. The stock had a trading volume of 168,566 shares, compared to its average volume of 302,557. Nurix Therapeutics has a 52-week low of $7.52 and a 52-week high of $20.20. The company has a market cap of $570.49 million, a price-to-earnings ratio of -3.22 and a beta of 1.63. The company has a 50 day simple moving average of $11.70 and a 200 day simple moving average of $13.60.
Get Nurix Therapeutics alerts:Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the company. SVB Leerink lowered their target price on Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating on the stock in a report on Tuesday, December 13th. HC Wainwright lowered their target price on Nurix Therapeutics to $53.00 in a report on Thursday, October 13th. Finally, Morgan Stanley assumed coverage on Nurix Therapeutics in a report on Tuesday, October 11th. They set an "equal weight" rating and a $11.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.90.
Institutional Investors Weigh In On Nurix Therapeutics
Hedge funds have recently made changes to their positions in the business. BlackRock Inc. raised its position in shares of Nurix Therapeutics by 11.0% in the 3rd quarter. BlackRock Inc. now owns 3,723,090 shares of the company's stock worth $48,512,000 after buying an additional 367,743 shares during the period. State Street Corp raised its position in shares of Nurix Therapeutics by 9.2% in the 3rd quarter. State Street Corp now owns 2,312,224 shares of the company's stock worth $30,128,000 after buying an additional 195,453 shares during the period. Vanguard Group Inc. raised its position in shares of Nurix Therapeutics by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,160,866 shares of the company's stock worth $28,156,000 after buying an additional 49,370 shares during the period. FMR LLC raised its position in shares of Nurix Therapeutics by 59.6% in the 2nd quarter. FMR LLC now owns 1,790,655 shares of the company's stock worth $22,688,000 after buying an additional 668,632 shares during the period. Finally, Wasatch Advisors Inc. raised its position in shares of Nurix Therapeutics by 28.5% in the 1st quarter. Wasatch Advisors Inc. now owns 1,546,689 shares of the company's stock worth $21,669,000 after buying an additional 343,100 shares during the period. Institutional investors and hedge funds own 91.33% of the company's stock.Nurix Therapeutics Company Profile
(Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Further Reading
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.